The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PCSK9 inhibitor evolocumab to increase anticancer activities and reduce cardiotoxicity during doxorubicin and trastuzumab, as sequential treatment, through MyD88/NF-kB/mTORC1 pathways.
 
Vincenzo Quagliariello
No Relationships to Disclose
 
Simona Buccolo
No Relationships to Disclose
 
Martina Iovine
No Relationships to Disclose
 
Andrea Paccone
No Relationships to Disclose
 
Annamaria Bonelli
No Relationships to Disclose
 
Ernesta Cavalcanti
No Relationships to Disclose
 
Domenica Rea
No Relationships to Disclose
 
Michelino De Laurentiis
Honoraria - Amgen; AstraZeneca; Celgene; Eisai; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Eisai; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Speakers' Bureau - Novartis
Research Funding - Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Macrogenics; MSD; Novartis; Pfizer; Puma Biotechnology; Roche
 
Gerardo Botti
No Relationships to Disclose
 
Nicola Maurea
No Relationships to Disclose